-
Something wrong with this record ?
Blood metabolomic and transcriptomic signatures stratify patient subgroups in multiple sclerosis according to disease severity
AE. Oppong, L. Coelewij, G. Robertson, L. Martin-Gutierrez, KE. Waddington, P. Dönnes, P. Nytrova, R. Farrell, I. Pineda-Torra, EC. Jury
Status not-indexed Language English Country United States
Document type Journal Article
NLK
Directory of Open Access Journals
from 2018
PubMed Central
from 2018
Europe PubMed Central
from 2018
ROAD: Directory of Open Access Scholarly Resources
from 2018
- Publication type
- Journal Article MeSH
There are no blood-based biomarkers distinguishing patients with relapsing-remitting (RRMS) from secondary progressive multiple sclerosis (SPMS) although evidence supports metabolomic changes according to MS disease severity. Here machine learning analysis of serum metabolomic data stratified patients with RRMS from SPMS with high accuracy and a putative score was developed that stratified MS patient subsets. The top differentially expressed metabolites between SPMS versus patients with RRMS included lipids and fatty acids, metabolites enriched in pathways related to cellular respiration, notably, elevated lactate and glutamine (gluconeogenesis-related) and acetoacetate and bOHbutyrate (ketone bodies), and reduced alanine and pyruvate (glycolysis-related). Serum metabolomic changes were recapitulated in the whole blood transcriptome, whereby differentially expressed genes were also enriched in cellular respiration pathways in patients with SPMS. The final gene-metabolite interaction network demonstrated a potential metabolic shift from glycolysis toward increased gluconeogenesis and ketogenesis in SPMS, indicating metabolic stress which may trigger stress response pathways and subsequent neurodegeneration.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24005581
- 003
- CZ-PrNML
- 005
- 20240412130959.0
- 007
- ta
- 008
- 240405s2024 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.isci.2024.109225 $2 doi
- 035 __
- $a (PubMed)38433900
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Oppong, Alexandra E $u Division of Medicine, Department of Inflammation, University College London, London WC1E 6JF, UK
- 245 10
- $a Blood metabolomic and transcriptomic signatures stratify patient subgroups in multiple sclerosis according to disease severity / $c AE. Oppong, L. Coelewij, G. Robertson, L. Martin-Gutierrez, KE. Waddington, P. Dönnes, P. Nytrova, R. Farrell, I. Pineda-Torra, EC. Jury
- 520 9_
- $a There are no blood-based biomarkers distinguishing patients with relapsing-remitting (RRMS) from secondary progressive multiple sclerosis (SPMS) although evidence supports metabolomic changes according to MS disease severity. Here machine learning analysis of serum metabolomic data stratified patients with RRMS from SPMS with high accuracy and a putative score was developed that stratified MS patient subsets. The top differentially expressed metabolites between SPMS versus patients with RRMS included lipids and fatty acids, metabolites enriched in pathways related to cellular respiration, notably, elevated lactate and glutamine (gluconeogenesis-related) and acetoacetate and bOHbutyrate (ketone bodies), and reduced alanine and pyruvate (glycolysis-related). Serum metabolomic changes were recapitulated in the whole blood transcriptome, whereby differentially expressed genes were also enriched in cellular respiration pathways in patients with SPMS. The final gene-metabolite interaction network demonstrated a potential metabolic shift from glycolysis toward increased gluconeogenesis and ketogenesis in SPMS, indicating metabolic stress which may trigger stress response pathways and subsequent neurodegeneration.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Coelewij, Leda $u Division of Medicine, Department of Inflammation, University College London, London WC1E 6JF, UK
- 700 1_
- $a Robertson, Georgia $u Division of Medicine, Department of Inflammation, University College London, London WC1E 6JF, UK
- 700 1_
- $a Martin-Gutierrez, Lucia $u Division of Medicine, Department of Inflammation, University College London, London WC1E 6JF, UK
- 700 1_
- $a Waddington, Kirsty E $u Division of Medicine, Department of Inflammation, University College London, London WC1E 6JF, UK
- 700 1_
- $a Dönnes, Pierre $u Division of Medicine, Department of Inflammation, University College London, London WC1E 6JF, UK $u Scicross AB, Skövde, Sweden
- 700 1_
- $a Nytrova, Petra $u Department of Neurology and Centre of Clinical, Neuroscience, First Faculty of Medicine, General University Hospital and First Faculty of Medicine, Charles University in Prague, 500 03 Prague, Czech Republic
- 700 1_
- $a Farrell, Rachel $u Department of Neuroinflammation, University College London and Institute of Neurology and National Hospital of Neurology and Neurosurgery, London WC1N 3BG, UK
- 700 1_
- $a Pineda-Torra, Inés $u Division of Medicine, Department of Inflammation, University College London, London WC1E 6JF, UK
- 700 1_
- $a Jury, Elizabeth C $u Division of Medicine, Department of Inflammation, University College London, London WC1E 6JF, UK
- 773 0_
- $w MED00197302 $t iScience $x 2589-0042 $g Roč. 27, č. 3 (2024), s. 109225
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38433900 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240405 $b ABA008
- 991 __
- $a 20240412130952 $b ABA008
- 999 __
- $a ok $b bmc $g 2075959 $s 1215343
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2024 $b 27 $c 3 $d 109225 $e 20240215 $i 2589-0042 $m iScience $n iScience $x MED00197302
- LZP __
- $a Pubmed-20240405
